Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAN 90806

Drug Profile

PAN 90806

Alternative Names: CP-547,632; CP-632; OSI-632; PAN-90806

Latest Information Update: 16 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OSI Pharmaceuticals; Pfizer
  • Developer PanOptica; Pfizer
  • Class Antineoplastics; Eye disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Wet age-related macular degeneration
  • No development reported Diabetic retinopathy
  • Discontinued Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 16 Oct 2019 PAN 90806 is available for licensing as of 16 Oct 2019. www.panopticapharma.com
  • 11 Oct 2019 Topline efficacy and adverse events data from a phase-I/II trial in Wet age-related macular degeneration released by PanOptica
  • 11 Oct 2019 PanOptica plans pivotal trials for Wet age-related macular degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top